{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:08:22Z","timestamp":1784167702960,"version":"3.55.0"},"reference-count":113,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and S\u00e9zary syndrome; PTCLs; and adult T-cell leukemia\/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms.<\/jats:p>","DOI":"10.3390\/ijms25042203","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:47:45Z","timestamp":1707713265000},"page":"2203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review"],"prefix":"10.3390","volume":"25","author":[{"given":"Montserrat","family":"Fern\u00e1ndez-Guarino","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital Universitario Ram\u00f3n y Cajal, Instituto de Investigaci\u00f3n Sanitaria Ram\u00f3n y Cajal (Irycis), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital 12 de Octubre, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1341","authenticated-orcid":false,"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario de la Princesa, Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica de la Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome\u2014Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1291259","DOI":"10.3389\/fimmu.2023.1291259","article-title":"Advancements in the treatment of mycosis fungoides and Sezary syndrome: Monoclonal antibodies, immunotherapies, and Janus kinase inhibitors","volume":"14","author":"Quadri","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1284045","DOI":"10.3389\/fimmu.2023.1284045","article-title":"Advances in the treatment of mycoses fungoides and Sezary syndrome: A narrative update in skin-directed therapies and immune-based treatments","volume":"14","author":"Stuver","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jcph.1564","article-title":"Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma","volume":"60","author":"Mukai","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11899-012-0124-3","article-title":"Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas","volume":"7","author":"Tobinai","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_10","first-page":"918","article-title":"Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms","volume":"87","author":"Voso","year":"2002","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.1998.tb01188.x","article-title":"IgG-Fc-mediated effector functions: Molecular definition of interaction sites for effector ligands and the role of glycosylation","volume":"163","author":"Jefferis","year":"1998","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5045\/kjh.2011.46.3.148","article-title":"Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent(R) Technology","volume":"46","author":"Matsushita","year":"2011","journal-title":"Korean J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-05-2619","article-title":"Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa","volume":"12","author":"Iida","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2015-02-625251","article-title":"Mogamulizumab: 2 birds, 1 stone","volume":"125","author":"Wilcox","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020","volume":"18","author":"Horwitz","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/1346-8138.15707","article-title":"Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020","volume":"48","author":"Ohtsuka","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_23","unstructured":"Calzado-Villareal, L., Fernandez de Misa, R., Lopez-Lerma, I., Marin-Niebla, A., Mar\u00edn-Palomo, A., Muniesa-Montserrat, C., Novella-Canales, S., Rodriguez Pinilla, S.M., and Zapatero, A. (2021). Gu\u00eda Multidisciplinar Para El Abordaje Diagn\u00f3stico Y Terap\u00e9utico Del Paciente Con Linfoma Cut\u00e1neo Primario, \u00d3sea GEdLyTAdM, (GELTAMO)."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sugaya, M. (2021). Clinical Guidelines and New Molecular Targets for Cutaneous Lymphomas. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011079"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: Updates and Review of Current Therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr. Treat. Opt. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1080\/10428194.2021.1888376","article-title":"Clinical characteristics and outcomes of black patients with mycosis fungoides and S\u00e9zary syndrome: A subgroup analysis of the phase III MAVORIC trial","volume":"62","author":"Johnson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and S\u00e9zary Syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, T., Sun, J., Li, J., Zhao, Y., Zhang, T., Yang, R., and Ma, X. (2021). Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: An update evidence from 14 studies. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08363-w"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1080\/10428194.2021.1953007","article-title":"Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial","volume":"62","author":"Horwitz","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3324\/haematol.2017.177279","article-title":"Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas","volume":"103","author":"Kitadate","year":"2018","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/ejh.13474","article-title":"Clinical efficacy of mogamulizumab for relapsed\/refractory aggressive adult T-cell leukemia\/lymphoma: A retrospective analysis","volume":"105","author":"Satake","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13731","DOI":"10.1111\/dth.13731","article-title":"Successful treatment of CCR4+ mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy","volume":"33","author":"Fujimura","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0959-8049(21)00715-2","article-title":"Patient characteristics of long-term responders to mogamulizumab: Results from the MAVORIC study","volume":"156","author":"Kim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cjp2.180","article-title":"Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia\/lymphoma","volume":"7","author":"Fujii","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/1346-8138.14111","article-title":"Successful treatment of relapsed folliculotropic mycosis fungoides with mogamulizumab followed by intensity-modulated radiotherapy","volume":"45","author":"Fujimura","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e14805","DOI":"10.1111\/dth.14805","article-title":"A case of mycosis fungoides successfully treated with combination of bexarotene and mogamulizumab","volume":"34","author":"Hisamoto","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15858","DOI":"10.1111\/dth.15858","article-title":"Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series","volume":"35","author":"Amagai","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.2147\/CMAR.S377015","article-title":"Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas","volume":"14","author":"Caruso","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjd.19720","article-title":"Real-world experience of using mogamulizumab in relapsed\/refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"184","author":"Molloy","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jouandet, M., Nakouri, I., Nadin, L., Kieny, A., Samimi, M., Adamski, H., Quereux, G., Chaby, G., Dompmartin, A., and L\u2019Orphelin, J.M. (2022). Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study. Cancers, 14.","DOI":"10.3390\/cancers14071659"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: A retrospective single-centre case series","volume":"186","author":"Trum","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sezary syndrome: A multicentre, retrospective, real-world French study","volume":"37","author":"Quereux","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(21)00659-6","article-title":"Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sezary syndrome treated with mogamulizumab or vorinostat: Combining Australian real-world evidence and MAVORIC phase 3 trial data","volume":"156","author":"Remak","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14737140.2020.1760096","article-title":"Mogamulizumab in the treatment of advanced mycosis fungoides and S\u00e9zary syndrome: Safety and efficacy","volume":"20","author":"Lewis","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","article-title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma","volume":"21","author":"Porcu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.13220","article-title":"Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma","volume":"102","author":"Ishitsuka","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamadermatol.2018.0884","article-title":"Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and S\u00e9zary Syndrome","volume":"154","author":"Dai","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-018-2456-9","article-title":"Severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with residual mogamulizumab concentration","volume":"107","author":"Hosoi","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12185-021-03250-3","article-title":"Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation","volume":"115","author":"Inoue","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ejh.13728","article-title":"Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma","volume":"108","author":"Nosaka","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","article-title":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","volume":"107","author":"Tanaka","year":"2022","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12185-022-03447-0","article-title":"Mogamulizumab for post-transplant relapse of adult T-cell leukemia\/lymphoma: A case study","volume":"117","author":"Hirosawa","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2012.142","article-title":"Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory\/relapsed myeloma patients","volume":"48","author":"Kroger","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hon.2712","article-title":"Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience","volume":"38","author":"Sakamoto","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: Impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.21873\/anticanres.14527","article-title":"Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia\/lymphoma","volume":"40","author":"Jo","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.14797","article-title":"Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms","volume":"32","author":"Masuda","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","article-title":"Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression","volume":"175","author":"Schmiedel","year":"2018","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100629","DOI":"10.1016\/j.adro.2020.11.014","article-title":"Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome","volume":"6","author":"Fong","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1182\/blood.V128.22.4165.4165","article-title":"A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)","volume":"128","author":"Kim","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jjco\/hyy172","article-title":"Radiation-induced dermatitis after administration of mogamulizumab for adult T-cell leukaemia\/lymphoma: A multi-institutional retrospective study","volume":"49","author":"Maemoto","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e13487","DOI":"10.1111\/dth.13487","article-title":"Successful treatment of mogamulizumab-resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment","volume":"33","author":"Ohuchi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.23112","article-title":"The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients","volume":"87","author":"Kim","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2018-99-114819","article-title":"Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study","volume":"132","author":"Zinzani","year":"2018","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12105-017-0840-z","article-title":"Large Cell Transformation of Oral Mycosis Fungoides","volume":"12","author":"Sultan","year":"2018","journal-title":"Head. Neck Pathol."},{"key":"ref_78","first-page":"8118","article-title":"Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: A case series","volume":"26","author":"Teoli","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jdcr.2020.12.035","article-title":"Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sezary syndrome","volume":"9","author":"Breen","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2021.11.022","article-title":"Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-cell lymphoma","volume":"20","author":"Asokan","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.1502139","article-title":"Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing","volume":"196","author":"Nosbaum","year":"2016","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","article-title":"Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma","volume":"4","author":"Saito","year":"2020","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic Characterization of Mogamulizumab-associated Rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or S\u00e9zary Syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/S2352-3026(22)00354-4","article-title":"Bone granulomatous infiltrate associated with mogamulizumab in a patient with mycosis fungoides","volume":"10","author":"Pham","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1684\/ejd.2021.4179","article-title":"Scarring alopecia developing after mogamulizumab-associated rash","volume":"31","author":"Raval","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jdcr.2021.10.034","article-title":"Alopecia areata after mogamulizumab treatment","volume":"19","author":"Raval","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"Darbord","year":"2022","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.14634","article-title":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma","volume":"181","author":"Tokunaga","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1346-8138.12419","article-title":"Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: Cutaneous adverse reactions may predict the prognosis","volume":"41","author":"Yonekura","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"adv00158","DOI":"10.2340\/00015555-3527","article-title":"Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review","volume":"100","author":"Trager","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_95","first-page":"1355","article-title":"Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T-cell lymphoma","volume":"19","author":"Lehner","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1684\/ejd.2021.4002","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: Three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000368772","article-title":"Concomitant mycosis fungoides and vitiligo: How mycosis fungoides may contribute to melanocyte destruction","volume":"230","author":"Herrmann","year":"2015","journal-title":"Dermatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2340\/00015555-2027","article-title":"Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient","volume":"95","author":"Honda","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia \/ lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1111\/jdv.18868","article-title":"Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sezary syndrome","volume":"37","author":"Lazaridou","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00277-016-2594-1","article-title":"Toxic epidermal necrolysis in adult T cell leukemia\/lymphoma treated with mogamulizumab","volume":"95","author":"Tanba","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2133.1987.tb04904.x","article-title":"Generalized vitiligo following Sezary syndrome","volume":"116","author":"Alcalay","year":"1987","journal-title":"Br. J. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2133.2000.03851.x","article-title":"Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: Four cases. The French Study Group of Cutaneous Lymphomas","volume":"143","author":"Bouloc","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2133.2005.06877.x","article-title":"Pathogenetic mechanisms of vitiligo in a patient with Sezary syndrome","volume":"153","author":"Knol","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/jdv.16033","article-title":"Radiation recall dermatitis induced by mogamulizumab","volume":"34","author":"Sasaki","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_106","first-page":"e488","article-title":"Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.annder.2020.09.576","article-title":"Ecthyma gangrenosum complicating mogamulizumab treatment of S\u00e9zary syndrome","volume":"148","author":"Valois","year":"2021","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12185-018-2552-x","article-title":"Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution","volume":"109","author":"Kamachi","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2169\/internalmedicine.8781-16","article-title":"Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not Otherwise Specified after Mogamulizumab Treatment","volume":"56","author":"Tanaka","year":"2017","journal-title":"Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14740\/wjon1255","article-title":"The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab","volume":"11","author":"Wang","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjd.21018","article-title":"Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in S\u00e9zary syndrome","volume":"186","author":"Roelens","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","article-title":"Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash","volume":"14","author":"Trum","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-021-00624-7","article-title":"Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management","volume":"12","author":"Musiek","year":"2022","journal-title":"Dermatol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:58:54Z","timestamp":1760104734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":113,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25042203"],"URL":"https:\/\/doi.org\/10.3390\/ijms25042203","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}